Although biologic DMARDs (bDMARDs) such as B-cell depleting antibodies, TNF-α inhibitors (soluble TNF receptor and monoclonal antibodies (mAbs) to TNF-α), IL-6 inhibitors (mAbs to IL-6 receptor) and co-stimulatory molecule inhibitors (soluble CTLA-4-Fc) have demonstrated the potential to significantly improve symptoms and prevent disease progression in RA patients, they are immunogenic and can increase the risk of serious infections [2]. The gene discussed is IL6; the disease is rheumatoid arthritis.